b'Scientific Session Abstracts SATURDAY APRIL 20, 2024 TEVAR timing 14 days 14 - 30 days 30 daysN=1,304 N=188 N=362 p-valueOperative CharacteristicsAnesthesia (general) 1,276 (97.9%) 183 (97.3%) 355 (98.1%) 0.856 2 13 (1.0%) 6 (3.2%) 5 (1.4%)3 341 (26.2%) 59 (31.4%) 159 (43.9%)ASA class 0.0014 877 (67.3%) 122 (64.9%) 195 (53.9%)5 73 (5.6%) 1 (0.5%) 3 (0.8%)IVUS 982 (75.3%) 152 (80.9%) 262 (72.4%) 0.092Maximal aortic diameter (mm) 42.512.4 43.910.4 47.412.5 0.001Elective 475 (36.4%) 111 (59.0%) 283 (78.2%)Urgency Urgent 586 (44.9%) 71 (37.8%) 67 (18.5%) 0.001Emergent 243 (18.6%) 6 (3.2%) 12 (3.3%)Aneurysmal108 (8.3%) 25 (13.3%) 103 (28.5%) 0.001degenerationProgression of94 (7.2%) 24 (12.8%) 72 (19.9%) 0.001Indication ofDissectionTEVAR Persistent Hypertension 319 (24.5%) 43 (22.9%) 48 (13.3%) 0.001Persistent pain 1,226172 (91.5%) 296 (81.8%) 0.001(94.0%)Discrete variables presented as case numbers (%), continuous variables presented as meanstandard deviation. BMI, body mass index; COPD, chronic obstructive pulmonary disease; DM, diabetes melitus; HTN, hypertension; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cerebrovascular disease; EF, ejection fraction; CABG, coronary artery bypass grafting; CEA, carotid endarterectomy; CAS, carotid artery stenting; PCI, percutaneous coronary intervention; PVI, peripheral vascular intervention; ACE, Angiotensin converting enzyme; ASA, American Society of Anesthesiologists; IVUS, intravascular ultrasound.54SOUTHERN CALIFORNIA VASCULAR SURGICAL SOCIETY'